Summary
Purpose The Src family of kinases may play a role in the development and progression of gastric cancer. We evaluated the activity and safety of saracatinib an oral, anilinoquinazolone, non-receptor tyrosine kinase inhibitor targeting Src kinases, in patients with metastatic or locally advanced gastric carcinoma. Methods Eligible patients who had received ≤1 prior line of chemotherapy for metastatic disease received saracatinib 175 mg/day of a 28 day cycle until progression. The primary endpoint was the objective response and/or prolonged stable disease rate (pSD ≥ 16 weeks). Results Ten patients with gastric carcinoma and 11 with adenocarcinoma of the gastroesophageal junction received a median of 2 cycles (range 1–10 cycles) of treatment per patient. 17 patients were evaluable for response. No objective response was seen. One patient experienced prolonged Stable disease (pSD). Three patients had SD and 13 progressive disease. Median overall survival was 7.8 months (95% CI, 3.9–12.2 months) and median time to progression was 1.8 months (95% CI: 1.5–1.9 months). Grade 3 events possibly related to saracatinib included: fatigue (2 patients), hypoxia (2) anemia (3) and lymphopenia (2). Conclusion Saracatinib has insufficient activity as a single agent in patients with advanced gastric adenocarcinoma to warrant further investigation. Further development in gastric cancer would require rational drug combinations or identification of a tumor phenotype sensitive to Src inhibition.
Similar content being viewed by others
References
Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137–2150
Jemal A, Siegal R, Xu J et al (2010) Cancer statistics, 2010 CA. Cancer J Clin 60:277–300
Wagner AD, Grothe W, Haerting J et al (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24:2903–2909
Bang YE, Van Cutsem E, Feyerislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742):687–697
Cunningham D, Starling N, Rao S et al (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358:36–46
Kang YK, Kang WK, Shin DB et al (2009) Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III non-inferiority trial. Ann Oncol 20:666–673
Thomas SM, Brugge JS (1997) Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol 13:513–609
Summy J, Gallick GE (2003) Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22:337–358
Yeatman TJ (2004) A renaissance for SRC. Nat Rev Cancer 4:470–480
Jawhari AUM, Noda M, Pignatelli M et al (1999) Up-regulated cytoplasmic expression, with reduced membranous distribution, of src substrate p 120(ctn) in gastric carcinoma. J Pathol 189:180–185
Karatzas G, Karayiannakis AJ, Syrigos KN et al (2000) Expression patterns of the E-cadherin-catenin-cell-cell adhesion complex in gastric cancer. Hepatogastroenterology 47:1465–1469
Karayiannakis AJ, Syrigos KN, Alexiou D et al (1999) Expression patterns of the novel catenin p120cas in gastrointestinal cancers. Anticancer Res 19:4401–4405
Takekura N, Yasui W, Yoshida K et al (1990) pp 60c-src protein kinase activity in human gastric carcinomas. Int J Cancer 45:847–851
Masaki T, Shiratori Y, Okada H et al (2000) pp 60c-src activation in gastric carcinoma: a preliminary study. Am J Gastroenterol 95:837–838
Humar B, Fukuzawa R, Blair V et al (2007) Destabilized adhesion in the gastric proliferative zone and c-Src kinase activation mark the development of early diffuse gastric cancer. Cancer Res 67:2480–2489
Okamoto W, Okamoto I, Yoshida T et al (2010) Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition. Mol Cancer Ther 9:1188–1197
Gallagher NJ, Lockton AJ, Macpherson M, et al (2005). A phase I multiple ascending dose study to assess the safety, tolerability and pharmacokinetics of AZD0530, a highly selective, orally available, dual specific Src-Abl kinase inhibitor [abstract 3972]. Proc Amer Assoc Cancer Res 46
Baselga J, Cervantes A, Martinelli E, et al (2010) Phase I safety, pharmacokinetics, and inhibition of Src activity study of saracatinib in patients with solid tumors. Clin Cancer Res 16:e pub (Oct 1st)
Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1–10
Therasse P, Arbuck S, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205–216
Moehler MH, Hartmann JT, Lordick F, et al (2010). An open-label, multicenter phase II trial of sunitinib for patients with chemo refractory metastatic gastric cancer. J Clin Oncol 28(suppl; abstr e14503)
Yamada Y, Doi T, Muro K, et al (2009) Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer: main results. ASCO Gastrointestinal Cancer Symposium. Abs 77
Lara PN, Longmate J, Evans CP et al (2009) A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study. Anticancer Drugs 20:179–184
Bertotti A, Bracco C, Girolami F et al (2010) Inhibition of Src impairs the growth of Met-addicted gastric tumors. Clin Cancer Res 16:3933–3941
Yoshida T, Okamoto I, Okamoto W et al (2010) Effects of src inhibitors on cell growth and epidermal growth factor receptor and Met signaling in gefitinib-resistant non-small cell lung cancer cells with aquired Met amplification. Cancer Sci 101:167–172
Fury M, Baxi S, Shen R et al (2011) Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res 31(1):249–253
Acknowledgements
This trial was supported by funding from, and drug was supplied by the Cancer Therapeutics Evaluation Program, US National Cancer Institute
Conflict of interest statement
None of the authors of this manuscript have any conflict of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mackay, H.J., Au, H.J., McWhirter, E. et al. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest New Drugs 30, 1158–1163 (2012). https://doi.org/10.1007/s10637-011-9650-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10637-011-9650-4